Primary contact

Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture (IRC) technology, Atreca has an unparalleled insight into how cancer patients' immune responses can drive better clinical outcomes. This insight can then help transform the discovery and development of therapeutics, vaccines, and diagnostics in multiple therapeutic areas where an immune response drives clinical outcomes. The company was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today's patients is the key to creating a new generation of therapies. It has established partnerships with major pharmaceutical companies, non-profit foundations, academic institutions, and governmental entities.
Primary contact

Funding 💰

Total $97.9M
Select investors Wellington Management, Cormorant Asset Management, Mission Bay Capital, GlaxoSmithKline, Bill & Melinda Gates Foundation, Evolution Corporate Advisors
Last update: May 13, 2018